NASDAQ$BPMC
Blueprint Medicines Corp · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Blueprint Medicines experienced significant growth with two approved precision therapies and near-term opportunities.
Blueprint Medicines reported strong Q3 2020 results, highlighted by total revenues of $745.1 million, including $6.3 million from product sales, and a net income of $634.0 million. The company launched GAVRETO in the U.S. and prepared to file a supplemental NDA for AYVAKIT. Ended Q3 with approximately $1.4 billion in cash.
- Received FDA approval and launched GAVRETO™ for RET fusion-positive non-small cell lung cancer.
- Announced top-line EXPLORER and PATHFINDER data for AVYAKITTM in advanced systemic mastocytosis; plan to submit supplemental NDA to FDA in Q4 2020.
- Received European Commission approval of AYVAKYT® for PDGFRA D842V mutant gastrointestinal stromal tumors.
- Ended Q3 2020 with approximately $1.4 billion in cash driven by the upfront payments from the Roche collaboration signed during the quarter.
Headline financials
Revenue & EPS history
Blueprint Medicines · Revenue · Quarterly
$745M
Forward guidance
Blueprint Medicines anticipates several key milestones, including submitting a supplemental NDA for avapritinib, obtaining U.S. approval of GAVRETO for RET-altered thyroid cancers, and initiating a global Phase 1 trial for BLU-945.
Tailwinds
- Submit a supplemental new drug application to the FDA for avapritinib for the treatment of patients with advanced SM in the fourth quarter of 2020.
- Obtain U.S. approval of GAVRETO for RET-altered thyroid cancers in the first quarter of 2021.
- Initiate a global Phase 1 dose-escalation trial for BLU-945 in EGFR-mutated NSCLC in the first half of 2021.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 16 quarterly earnings reports
+2.5%
Avg return
Earnings day
+2.6%
Avg return
5 days after
+6.3%
Avg return
30 days after
68%
27 / 40 earnings
Positive
+24.7%
Q3 2023
Best reaction
-20.7%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2025 | +10.9% | +11.0% | +13.3% | |
| Q4 2025 | -8.1% | -10.9% | -13.4% | |
| Q3 2025 | +4.9% | +10.2% | +14.0% | |
| Q2 2024 | -10.7% | -14.4% | -11.8% | |
| Q1 2024 | +13.0% | +14.3% | +11.2% | |
| Q4 2023 | +17.5% | +18.9% | +17.9% | |
| Q3 2023 | +24.7% | +34.1% | +55.8% | |
| Q2 2023 | -20.7% | -26.6% | -21.2% | |
| Q1 2023 | +8.4% | +4.5% | +12.1% | |
| Q4 2022 | +5.0% | -1.2% | +2.4% | |
| Q3 2022 | -11.1% | -19.0% | -8.5% | |
| Q2 2022 | +18.0% | +34.7% | +46.0% | |
| Q1 2022 | +5.9% | -4.9% | -4.8% | |
| Q4 2021 | -17.0% | -19.9% | -21.9% | |
| Q3 2021 | +7.9% | +6.4% | -3.1% | |
| Q2 2021 | +6.0% | +3.8% | +13.2% | |
| Q1 2021 | -1.0% | — | — | |
| Q4 2020 | +3.8% | — | — | |
| Q3 2020 | -2.2% | — | — | |
| Q2 2020 | -0.8% | — | — | |
| Q1 2020 | +0.7% | — | — | |
| Q4 2019 | +3.5% | — | — | |
| Q3 2019 | +10.4% | — | — | |
| Q2 2019 | -9.2% | — | — | |
| Q1 2019 | +9.0% | — | — | |
| Q4 2018 | +1.4% | — | — | |
| Q3 2018 | -1.4% | — | — | |
| Q1 2018 | +1.3% | — | — | |
| Q4 2017 | +5.5% | — | — | |
| Q3 2017 | +4.8% | — | — | |
| Q2 2017 | -9.8% | — | — | |
| Q1 2017 | -11.6% | — | — | |
| Q4 2016 | +13.0% | — | — | |
| Q3 2016 | +9.9% | — | — | |
| Q2 2016 | +2.4% | — | — | |
| Q1 2016 | -1.4% | — | — | |
| Q4 2015 | +4.6% | — | — | |
| Q3 2015 | +1.4% | — | — | |
| Q2 2015 | +2.5% | — | — | |
| Q1 2015 | +8.4% | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro